Eloxx Pharmaceuticals, Inc. Liquidation Value
ELOX
Other
Cash & Equivalents
$4.79M
As of 2025-12-31
Current Price: N/A
Key Metrics
Cash Liquidation Value
Cash minus Total Obligations
Cash: $4.79M
Total Obligations: -$18.18M
$-13.39M
Per share: $-2.80
Period: 2025-12-31
Liquid Liquidation Value
Cash + AR minus Total Obligations
Cash: $4.79M
AR: $0
Total Obligations: -$18.18M
$-13.39M
Per share: $-2.80
Period: 2025-12-31
Operating Liquidation Value
Cash + AR + Inventory minus Total Obligations
Cash: $4.79M
AR: $0
Inventory: $0
Total Obligations: -$18.18M
$-13.39M
Per share: $-2.80
Period: 2025-12-31
Build your own liquidation scenario
Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.
Liquidation Ladder
| Metric | Total | Per Share |
|---|---|---|
| Cash Liquidation Value | $-13.39M | $-2.80 |
| Liquid Liquidation Value | $-13.39M | $-2.80 |
| Operating Liquidation Value | $-13.39M | $-2.80 |
Key Components (as of 2025-12-31)
| Cash & Equivalents | $4.79M |
| Accounts Receivable | N/A |
| Inventory | N/A |
| Current Liabilities | $17.18M |
| Long-term Debt | $1.00M |
| Op. Lease Liability | $0 |
| Finance Lease | N/A |
| Shares Outstanding | 4.8M |
Explore all 146 XBRL tags and build your own scenario → Open Calculator
Historical
| Period | Cash | AR | Inventory | AP | Curr Liab | LT Debt | Op Lease | Fin Lease |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $4.79M | N/A | N/A | $2.71M | $17.18M | $1.00M | $0 | N/A |
| 2024-12-31 | $111,000 | N/A | N/A | $5.35M | $27.31M | $0 | $4,000 | N/A |
| 2023-12-31 | $1.13M | N/A | N/A | $5.70M | $22.70M | $1.61M | $135,000 | N/A |
| 2023-09-30 | $4.78M | N/A | N/A | $3.13M | $23.47M | $4.62M | $318,000 | N/A |
| 2023-06-30 | $4.33M | N/A | N/A | $3.12M | $21.25M | $4.79M | $496,000 | N/A |
| 2023-03-31 | $4.90M | N/A | N/A | $2.43M | $19.46M | $4.74M | $673,000 | N/A |
| 2022-12-31 | $19.21M | N/A | N/A | $3.02M | $23.09M | $11.72M | $847,000 | N/A |
| 2022-09-30 | $24.55M | N/A | N/A | $1.59M | $21.68M | $11.57M | $1.02M | N/A |
▼ Community Notes